This study investigated which subtype of muscarinic receptor in mesenteric arteries from SHRs mediates the loss of the release of nitric oxide (NO) or endothelium-derived hyperpolarizing factor (EDHF) in spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. After SHRs and WKY rats were killed, their superior mesenteric arteries were isolated to perform the vascular relaxation study. Acetylcholine (ACh, 1 nM-1 microM)-induced relaxation was in a concentration-dependent manner and was impaired in mesenteric arterial rings obtained from the SHR group, whereas nitroglycerin (10 nM-1 microM)-induced relaxation was not affected in endothelium-denuded rings obtained from the hypertensive rat. In the presence of N(omega)-nitro-L-arginine (L-NNA; 0.1 mM) or methylene blue (10 microM), the ACh-induced relaxation was partially attenuated in both SHRs and WKY rats. The relaxation of ACh was partially inhibited by 4-aminopyridine (4-AP; 1 mM), apamin (APM; 1 microM), or charybdotoxin (CTX; 0.1 microM) in WKY rats, whereas that relaxation was not affected by 4-AP, APM, or CTX in SHRs. However, the L-NNA-resistant relaxation of ACh was further inhibited by APM or CTX in WKY rats but not in SHRs. When arterial rings were precontracted by 60 mM K+, the ACh-induced relaxation was not significantly different in SHRs and WKY rats. However, this relaxation was abolished by L-NNA (0.1 mM) in both strains. In addition, the M3 muscarinic antagonist, 4-diphenylacetoxy-N-methylpiperidine was the most potent in inhibiting the relaxation of ACh, being more potent than pirenzepine and methoctramine, which preferentially block M1 and M2 receptors in the mesenteric artery of WKY rats, respectively. 2-Nitro-4-carboxyphenyl-N,N-diphenylcarbamate (1 microM) almost abolished the relaxation of ACh, but not of A23187, in SHRs and WKY rats. These results suggest that NO and EDHF are released from the endothelium of rat mesenteric artery on the activation of muscarinic M3-receptor by ACh, and the loss of ACh-induced relaxation in small arteries of SHRs is mainly through reducing the release or activity or both of EDHF.